Recent studies have uncovered the critical role that gut microbiota—the trillions of bacteria living in our digestive system—play in colorectal cancer treatment efficacy. These microbes actively interact with cancer therapies, influencing how well a patient responds to treatment. A balanced and diverse gut microbiome can enhance the effectiveness of chemotherapy and immunotherapy, while an imbalanced microbiome, or dysbiosis, may hinder response or lead to complications like chemotherapy-induced diarrhea.

For example, certain bacterial species, such as Fusobacterium nucleatum, have been linked to colorectal cancer progression and chemotherapy resistance. Meanwhile, beneficial bacteria like Bifidobacterium are thought to improve the immune system’s ability to fight tumors. Probiotics, prebiotics, and dietary interventions are being studied as potential therapies to modify gut bacteria in cancer patients, and some clinical trials are exploring fecal microbiota transplantation (FMT) to restore balance after aggressive treatments.

The exact mechanisms by which the gut microbiome affects treatment outcomes are still being researched, but personalized approaches, such as profiling a patient’s microbiome before starting treatment, could shape the future of cancer care.

 

Combining non chemical treatment options like ECCT electric field helps to balance microbiomes that play a role in enhancing chemotherapy efficiency.